Login
$COR
$330.00 -$1.00 (0.3%) Close

Company Executives

$COR Management Team

Mr. Bennett Murphy

Senior Vice President

Investor Relations

Age -
Compensation -
Sex Male

Mr. D. Mark Durcan

Non-Executive Independent Chairman of the Board

Age 64
Compensation $375.2K USD
Sex Male

Dr. Robert Mauch

President

Chief Executive Officer

Director

Age 59
Compensation $18.26M USD
Sex Male

Mr. James Cleary

Chief Financial Officer

Executive Vice President

Age 62
Compensation $6.522M USD
Sex Male

Ms. Silvana Battaglia

Chief Human Resources Officer

Executive Vice President

Age 58
Compensation $3.663M USD
Sex Female

Mr. Pawan Verma

Executive Vice President

Chief Data and Information Officer

Age 49
Compensation -
Sex Male

Ms. Elizabeth Campbell

Executive Vice President

Chief Legal Officer

Age 51
Compensation $5.177M USD
Sex Female
Directors
11
serving now
Independent
10 of 11
stated in the proxy
Average tenure
4.4 years
from year joined
CEO also chairs the board
No
D. Mark Durcan
Director Age On board Independent Committees Other public boards 2025 pay Source
Werner Baumann
63 2023
3 years
Independent
Audit · Chair Compensation and Succession Planning Executive Special Litigation · Chair
None stated $383,095
Frank K. Clyburn
61 2024
2 years
Independent
Compliance and Risk Finance
Revolution Medicines, Inc. (Nasdaq: RVMD) $396,436
Ellen G. Cooper
61 2026
0 years
Independent None stated Lincoln National Corporation (NYSE: LNC) Not stated
D. Mark Durcan
64 2015
11 years
Independent
Executive · Chair
ASML Holding N.V. (Nasdaq: ASML) $375,217
Lon R. Greenberg
75 2013
13 years
Independent
Compliance and Risk Executive Finance Governance, Sustainability and Corporate Responsibility · Chair
None stated $330,225
Lorence H. Kim, M.D.
51 2022
4 years
Independent
Compensation and Succession Planning Executive Finance · Chair
Revolution Medicines, Inc. (Nasdaq: RVMD) $330,225
Robert P. Mauch
59 2024
2 years
Not independent
Executive
None stated Paid as CEO
Redonda G. Miller, M.D.
59 2023
3 years
Independent
Compliance and Risk · Chair Executive Governance, Sustainability and Corporate Responsibility Special Litigation
None stated $385,225
Dennis M. Nally
73 2020
6 years
Independent
Audit Compensation and Succession Planning · Chair Executive
Morgan Stanley (NYSE: MS) $345,706
Lori J. Ryerkerk
63 2025
1 year
Independent None stated Eaton Corporation (NYSE: ETN), Norfolk Southern Corp (NYSE: NSC) $192,390
Lauren M. Tyler
64 2023
3 years
Independent
Audit Governance, Sustainability and Corporate Responsibility Special Litigation
None stated $360,940

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Jan 22, 2026
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated

10-year pharmaceutical distribution agreement under which we distribute branded and generic pharmaceutical products to Walgreens pharmacies (US PVA)

With Walgreens Boots Alliance, Inc. Open in proxy
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated

Generics purchasing services arrangement providing access to generics and related products through a global sourcing arrangement (WBAD Arrangement)

With Walgreens Boots Alliance Development GmbH Open in proxy
Ornella Barra
Chief Operating Officer, International of WBA; director designated by WBA under the Shareholders Agreement
Amount not stated
January 2015 until May 27, 2025

Board seat designated by WBA under the Shareholders Agreement; Ms. Barra served as a director until May 27, 2025

Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
$6.275 billion in cash
June 2021

Acquisition of a majority of WBA's Alliance Healthcare businesses for cash plus two million shares of our Common Stock, subject to purchase price adjustments

With Walgreens Boots Alliance, Inc. Open in proxy
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated
through 2029

Extension of the US PVA and the WBAD Arrangement by three years through 2029

With Walgreens Boots Alliance, Inc. Open in proxy
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated
through 2031

Distribution agreement to supply branded and generic pharmaceutical products to WBA's Boots pharmacies in the United Kingdom

With Walgreens Boots Alliance, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support